Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options

American Academy of Pediatrics (2011) ADHD: Clinical Practice Guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 128:1007–1022 American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, Fourth Edition, Text Revision (DSM-IV-TR). American Psychiatric Association, Washington DC Antshel KM, Hargrave TM, Simonescu M, Kaul P, Hendricks K, Faraone SV (2011) Advances in understanding and treating ADHD. BMC Med 9:72 Arnold EL (2000) Methylphenidate vs. amphetamine: comparative review. J Atten Disord 3:200–211 Arnold LE, Christopher J, Huestis R, Smeltzer DJ (1978) Methylphenidate vs dextroamphetamine vs caffeine in minimal brain dysfunction: controlled comparison by placebo washout design with Bayes’ analysis. Arch Gen Psychiatry 35:463–473 Arnsten AF (2009) The emerging neurobiology of attention deficit hyperactivity disorder: the key role of the prefrontal association cortex. J Pediatr 154:I–S43 Arnsten AF (2006) Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways. J Clin Psychiatry 67(Suppl 8):7–12 Assmann SF, Pocock SJ, Enos LE, Kasten LE (2000) Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 355:1064–1069 Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Dopfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJ, Taylor E (2006) Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 15:476–495 Bellgrove MA, Barry E, Johnson KA, Cox M, Daibhis A, Daly M, Hawi Z, Lambert D, Fitzgerald M, McNicholas F, Robertson IH, Gill M, Kirley A (2008) Spatial attentional bias as a marker of genetic risk, symptom severity, and stimulant response in ADHD. Neuropsychopharmacology 33:2536–2545 Bonetti M, Gelber RD (2004) Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics 5:465–481 Borcherding BG, Keysor CS, Cooper TB, Rapoport JL (1989) Differential effects of methylphenidate and dextroamphetamine on the motor activity level of hyperactive children. Neuropsychopharmacology 2:255–263 Brennan AR, Arnsten AF (2008) Neuronal mechanisms underlying attention deficit hyperactivity disorder: the influence of arousal on prefrontal cortical function. Ann N Y Acad Sci 1129:236–245 Brown GL, Hunt RD, Ebert MH, Bunney WE Jr, Kopin IJ (1979) Plasma levels of d-amphetamine in hyperactive children serial behavior and motor responses. Psychopharmacology 62:133–140 Burkins JA, Ciaverelli R, Frampton KK, Henschen G, McCarthy DP, Nardozzi LJ, Saldarini C, Scherzer A, Wadle C (2010) Clinical practice guideline for patients with attention deficit/hyperactivity disorder. Magellan Health Services Inc, MA, USA. https://www.magellanprovider.com/MHS/MGL/providing_care/clinical_guidelines/clin_prac_guidelines/ADHD.pdf. Accessed 11 April 2012 Cai T, Tian L, Wong PH, Wei LJ (2011) Analysis of randomized comparative clinical trial data for personalized treatment selections. Biostatistics 12:270–282 Canadian Attention Deficit Disorder Resource Alliance (CADDRA) (2011) Canadian ADHD Practice (CAP) Guidelines, 3rd edn. Toronto, ON. http://www.caddra.ca/cms4/pdfs/caddraGuidelines2011.pdf. Accessed 11 April 2012 Carlson CL, Pelham WE Jr, Milich R, Dixon J (1992) Single and combined effects of methylphenidate and behavior therapy on the classroom performance of children with attention-deficit hyperactivity disorder. J Abnorm Child Psychol 20:213–232 Castellanos FX, Elia J, Kruesi MJ, Marsh WL, Gulotta CS, Potter WZ, Ritchie GF, Hamburger SD, Rapoport JL (1996) Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder. Neuropsychopharmacology 14:125–137 Christensen L, Sasane R, Hodgkins P, Harley C, Tetali S (2010) Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Curr Med Res Opin 26:977–989 Cohen J (1992) A power primer. Psychol Bull 112:155–159 Curatolo P, D’Agati E, Moavero R (2010) The neurobiological basis of ADHD. Ital J Pediatr 36:79 Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA (2011) Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med 154:37–49 Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie und Psychotherapie: Leitlinien zur Diagnostik und Therapie von psychischen Störungen im Säuglings-K-uJ (2007) Hyperkinetische Störungen (F90). http://www.awmf.org/uploads/tx_szleitlinien/028-019l_S1_Hyperkinetische_Stoerungen_ADHS_01.pdf. Accessed 5 April 2012 Dew RE, Kollins SH (2010) Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD. Expert Opin Pharmacother 11:2907–2913 Diamond A (2005) Attention-deficit disorder (attention-deficit/hyperactivity disorder without hyperactivity): a neurobiologically and behaviorally distinct disorder from attention-deficit/hyperactivity disorder (with hyperactivity). Dev Psychopathol 17:807–825 Dopheide JA (2009) The role of pharmacotherapy and managed care pharmacy interventions in the treatment of ADHD. Am J Manag Care 15:S141–S150 Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717 Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451–1467 Easton N, Steward C, Marshall F, Fone K, Marsden C (2007) Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain. Neuropharmacology 52:405–414 Efron D, Jarman F, Barker M (1997) Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 100:E6 Efron D, Jarman F, Barker M (1997) Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 100:662–666 Elia J (2005) Attention deficit/hyperactivity disorder: pharmacotherapy. Psychiatry (Edgmont) 2:27–35 Elia J, Borcherding BG, Potter WZ, Mefford IN, Rapoport JL, Keysor CS (1990) Stimulant drug treatment of hyperactivity: biochemical correlates. Clin Pharmacol Ther 48:57–66 Elia J, Borcherding BG, Rapoport JL, Keysor CS (1991) Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiatry Res 36:141–155 Elia J, Welsh PA, Gullotta CS, Rapoport JL (1993) Classroom academic performance: improvement with both methylphenidate and dextroamphetamine in ADHD boys. J Child Psychol Psychiatry 34:785–804 Faraone SV (2012) Understanding the effect size of lisdexamfetamine dimesylate for treating ADHD in children and adults. J Atten Disord 16:128–137 Faraone SV (2009) Using meta-analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths. P T 34:678–694 Faraone SV, Buitelaar J (2010) Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 19:353–364 Faraone SV, Glatt SJ (2009) A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 71:754–763 Faraone SV, Mick E (2010) Molecular genetics of attention deficit hyperactivity disorder. Psychiatr Clin N Am 33:159–180 Fegert JM, Slawik L, Wermelskirchen D, Nubling M, Muhlbacher A (2011) Assessment of parents’ preferences for the treatment of school-age children with ADHD: a discrete choice experiment. Expert Rev Pharmacoecon Outcomes Res 11:245–252 Findling RL (2008) Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review. Clin Ther 30:942–957 Froehlich TE, McGough JJ, Stein MA (2010) Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics. CNS Drugs 24:99–117 Goodman DW (2010) Lisdexamfetamine dimesylate (vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorder. P T 35:273–287 Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Dopfner M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal E, Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong IC, Zuddas A, Steinhausen HC, Taylor E (2011) European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 20:17–37 Graham J, Coghill D (2008) Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs 22:213–237 Heal DJ, Smith SL, Findling RL (2012) ADHD: current and future therapeutics. Curr Top Behav Neurosci 9:361–390 Heal DJ, Smith SL, Kulkarni RS, Rowley HL (2008) New perspectives from microdialysis studies in freely-moving, spontaneously hypertensive rats on the pharmacology of drugs for the treatment of ADHD. Pharmacol Biochem Behav 90:184–197 Hermens DF, Cooper NJ, Kohn M, Clarke S, Gordon E (2005) Predicting stimulant medication response in ADHD: evidence from an integrated profile of neuropsychological, psychophysiological and clinical factors. J Integr Neurosci 4:107–121 Hungund BL, Perel JM, Hurwic MJ, Sverd J, Winsberg BG (1979) Pharmacokinetics of methylphenidate in hyperkinetic children. Br J Clin Pharmacol 8:571–576 Jones SR, Gainetdinov RR, Wightman RM, Caron MG (1998) Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci 18:1979–1986 Kahlig KM, Binda F, Khoshbouei H, Blakely RD, McMahon DG, Javitch JA, Galli A (2005) Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci USA 102:3495–3500 Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765 Kuczenski R, Segal DS (1997) Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 68:2032–2037 Lagakos SW (2006) The challenge of subgroup analyses–reporting without distorting. N Engl J Med 354:1667–1669 Läkemedelsverket (2009) Läkemedelsbehandling av ADHD—Ny rekommendation. http://www.lakemedelsverket.se/upload/halso-och-sjukvard/behandlingsrekommendationer/ADHD-rek_webb.pdf. Accessed 5 April 2012 Lloyd A, Hodgkins P, Dewilde S, Sasané R, Falcner S, SB E (2011) Methylphenidate delivery mechanisms for the treatment of children with attention deficit hyperactivity disorder: Heterogeneity in parent preferences. Int J Technol Assess Health Care 27:215–223 Marcus SC, Wan GJ, Kemner JE, Olfson M (2005) Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 159:572–578 Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R (2006) A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol 16:687–698 May DE, Kratochvil CJ (2010) Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. Drugs 70:15–40 McDonagh M, Peterson K, Dana T, Thakurta S (2007) Drug Class Review on Pharamcologic Treatments for ADHD. http://www.ncbi.nlm.nih.gov/books/bookres.fcgi/adhd/pdfadhd.pdf. Accessed 27 September 2011. Oregon Health and Science University, Portland, Oregon Ministerio de Sanidad PSeI (2010) Guía de Práctica Clínica sobre el trastorno por déficit de atención con hiperactividad (TDAH) en niños y adolescentes. http://www.gencat.cat/salut/depsan/units/aatrm/pdf/gpc_tdah_hiperactividad_aiaqs2010_compl.pdf. Accessed 5 April 2012 Muhlbacher AC, Rudolph I, Lincke HJ, Nubling M (2009) Preferences for treatment of attention-deficit/hyperactivity disorder (ADHD): a discrete choice experiment. BMC Health Serv Res 9:149 National Health Service (2010) Prescription cost analysis, England–2010. http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/prescriptions/prescription-cost-analysis-england–2010. Accessed 1 June 2011 National Institute for Health and Clinical Excellence (2009) Diagnosis and management of ADHD in children, young people and adults. National Clinical Practice Guideline Number 72. London, UK. http://www.nice.org.uk/nicemedia/live/12061/42060/42060.pdf. Accessed 11 April 2012 Pappadopulos E, Jensen PS, Chait AR, Arnold LE, Swanson JM, Greenhill LL, Hechtman L, Chuang S, Wells KC, Pelham W, Cooper T, Elliott G, Newcorn JH (2009) Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment. J Am Acad Child Adolesc Psychiatry 48:501–510 Pelham WE, Aronoff HR, Midlam JK, Shapiro CJ, Gnagy EM, Chronis AM, Onyango AN, Forehand G, Nguyen A, Waxmonsky J (1999) A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder. Pediatrics 103:e43 Pelham WE, Gnagy EM, Chronis AM, Burrows-MacLean L, Fabiano GA, Onyango AN, Meichenbaum DL, Williams A, Aronoff HR, Steiner RL (1999) A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 104:1300–1311 Pelham WE, Gnagy EM, Greiner AR, Hoza B, Hinshaw SP, Swanson JM, Simpson S, Shapiro C, Bukstein O, Baron-Myak C, McBurnett K (2000) Behavioral versus behavioral and pharmacological treatment in ADHD children attending a summer treatment program. J Abnorm Child Psychol 28:507–525 Pelham WE Jr, Carlson C, Sams SE, Vallano G, Dixon MJ, Hoza B (1993) Separate and combined effects of methylphenidate and behavior modification on boys with attention deficit-hyperactivity disorder in the classroom. J Consult Clin Psychol 61:506–515 Pelham WE Jr, Greenslade KE, Vodde-Hamilton M, Murphy DA, Greenstein JJ, Gnagy EM, Guthrie KJ, Hoover MD, Dahl RE (1990) Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 86:226–237 Pelham WE Jr, Wheeler T, Chronis A (1998) Empirically supported psychosocial treatments for attention deficit hyperactivity disorder. J Clin Child Psychol 27:190–205 Peto R (1990) Misleading subgroup analyses in GISSI. Am J Cardiol 66:771–772 Pliszka S (2007) Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46:894–921 Pliszka SR, Browne RG, Olvera RL, Wynne SK (2000) A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 39:619–626 Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS, McCracken JT, Swanson JM, Lopez M (2006) The Texas Children’s Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:642–657 Pocock SJ, Assmann SE, Enos LE, Kasten LE (2002) Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med 21:2917–2930 Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007) The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 164:942–948 Ramos-Quiroga JA, Bosch R, Castells X, Valero S, Nogueira M, Gomez N, Yelmo S, Ferrer M, Martinez Y, Casas M (2008) Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate: a chart review of Spanish adults with attention-deficit hyperactivity disorder. CNS Drugs 22:603–611 Reeves G, Anthony B (2009) Multimodal treatments versus pharmacotherapy alone in children with psychiatric disorders: implications of access, effectiveness, and contextual treatment. Paediatr Drugs 11:165–169 Robertson SD, Matthies HJ, Galli A (2009) A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters. Mol Neurobiol 39:73–80 Sanchez RJ, Crismon ML, Barner JC, Bettinger T, Wilson JP (2005) Assessment of adherence measures with different stimulants among children and adolescents. Pharmacotherapy 25:909–917 Scottish Intercollegiate Guidelines Network (2009) Management of attention deficit and hyperkinetic disorders in children and young people: a national clinical guideline. http://www.sign.ac.uk/pdf/sign112.pdf. Accessed 5 April 2012 Seixas M, Weiss M, Muller U (2012) Systematic review of national and international guidelines on attention-deficit hyperactivity disorder. J Psychopharmacol 26:753–765 Sharp WS, Walter JM, Marsh WL, Ritchie GF, Hamburger SD, Castellanos FX (1999) ADHD in girls: clinical comparability of a research sample. J Am Acad Child Adolesc Psychiatry 38:40–47 Solomon SD, Rice MM, Jablonski JA, Jose P, Domanski M, Sabatine M, Gersh BJ, Rouleau J, Pfeffer MA, Braunwald E (2006) Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 114:26–31 Steele M, Jensen PS, Quinn DM (2006) Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther 28:1892–1908 Stein MA, McGough JJ (2008) The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapy. Child Adolesc Psychiatr Clin N Am 17:475–490, xi–xii Sulzer D, Sonders MS, Poulsen NW, Galli A (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75:406–433 Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Rothenberger A, Sonuga-Barke E, Steinhausen HC, Zuddas A (2004) European clinical guidelines for hyperkinetic disorder–first upgrade. Eur Child Adolesc Psychiatry 13(Suppl 1):I7–I30 The MTA Cooperative Group (1999) A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal treatment study of children with ADHD. Arch Gen Psychiatry 56:1073–1086 The Royal Australasian College of Physicians (2009) Australian guidelines on attention deficit hyperactivity disorder (ADHD). http://www.nhmrc.gov.au/_files_nhmrc/file/publications/synopses/adhd/NHMRC-draft-ADHD-guidelines.pdf. Accessed 01 June 2011 Tian L, Cai T, Wei LJ (2009) Identifying subjects who benefit from additional information for better prediction of the outcome variables. Biometrics 65:894–902 Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ (2002) Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord 6(Suppl 1):S31–S43 Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Hitzemann R, Pappas N (1998) Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 155:1325–1331 Wigal SB, Kollins SH, Childress AC, Squires L (2009) A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health 3:17 Wilson HK, Cox DJ, Merkel RL, Moore M, Coghill D (2006) Effect of extended release stimulant-based medications on neuropsychological functioning among adolescents with attention-deficit/hyperactivity disorder. Arch Clin Neuropsychol 21:797–807 Winsberg BG, Press M, Bialer I, Kupietz S (1974) Dextroamphetamine and methylphenidate in the treatment of hyperactive-aggressive children. Pediatrics 53:236–241 Wolraich ML, Doffing MA (2004) Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. CNS Drugs 18:243–250 World Health Organization Collaborating Centre for Drug Statistics and Methodology (2011) ATC/DDD Index 2011. http://www.whocc.no/atc_ddd_index/ Zhao L, Cai T, Tian L, Uno H, Solomon SD, Wei LJ (2010) Stratifying subjects for treatment selection with censored event time data from a comparative study. Harvard University Biostatistics Working Paper Series 2010:Working Paper 122